Trial Profile
A Randomized, Open-label Phase 2 Study of Nanoliposomal Irinotecan (Nal-IRI)-Containing Regimens Versus Nab-Paclitaxel Plus Gemcitabine in Patients With Previously Untreated, Metastatic Pancreatic Adenocarcinoma
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 13 Oct 2022
Price :
$35
*
At a glance
- Drugs Irinotecan (Primary) ; Fluorouracil; Folinic acid; Gemcitabine; Oxaliplatin; Paclitaxel
- Indications Adenocarcinoma; Pancreatic cancer
- Focus Adverse reactions
- Sponsors Ipsen; Merrimack Pharmaceuticals
- 13 Oct 2022 This trial has been discontinued in Spain (Date of the global end of the trial : 07-Apr-2021), according to European Clinical Trials Database record.
- 10 Mar 2022 This trial has been completed in Italy, according to European Clinical Trials Database record.
- 21 Aug 2021 This trial has been discontinued in Sweden, according to European Clinical Trials Database record.